|
 |
| home > ebr > spring 2002 > a record-breaking us$27 billion of biotech deals supports strong pharma m&a activity in 2001 |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| The value of pharmaceutical mergers and acquisitions (M&A) in 2001 almost doubled to US$61 billion from US$34 billion in 2000 (excluding the US$76 billion formation that year of GlaxoSmithKline), bucking the significant downward trend witnessed in most other sectors. The number of deals remained stable at 334 in 2001, compared with 341 in 2000. In a period where most industries have experienced at least a 25 per cent downturn in M&A activity, the pharmaceutical sector has maintained its deal-making momentum. The aggregate value of deals is down because 2001 witnessed no mega-mergers to rival the prior year combination of Glaxo Wellcome and SmithKline Beecham. But with Amgen's US$17 billion bid for Immunex, plus a further US$10 billion of biotech deals in 2001, the foundations are being laid for a Big Biotech sector that will increasingly compete with Big Pharma. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
